Paper Details

  1. Home
  2. Paper Details

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.

Author: BhargavaPankaj, BurgerHerman, CotreauMonette M, EskensFerry A L M, EstevesBrooke, HayashiKunihiko, IsoeToshiyuki, ThomeerMaarten, VerweijJaap, de JongeMaja J A, van DoornLeni

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF receptor (VEGFR) tyrosine kinase inhibitor, in 41 patients with advanced solid tumors. The MTD was determined to be 1.5 mg/day. Tivozanib was well tolerated with manageable side effects, and encouraging and durable clinical activity was observed.
Paper Details　
Original Abstract of the Article :
PURPOSE: To assess the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF receptor (VEGFR) tyrosine kinase inhibitor. EXPERIMENTAL DESIGN: Dose levels of 1.0, 1.5, and 2.0 mg/d tivozanib for 28 d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-11-0411

データ提供：米国国立医学図書館（NLM）

Tivozanib: A New Oasis in the Desert of Advanced Cancer

The fight against cancer is a relentless journey through a vast and unforgiving desert. This research explores the potential of a new therapeutic oasis, tivozanib, a selective inhibitor of VEGF receptor tyrosine kinases. The study evaluated the safety, effectiveness, and pharmacokinetic properties of tivozanib in patients with advanced solid tumors. The results of this clinical trial provide encouraging evidence for the potential of tivozanib as a promising new treatment option for a range of cancers.

Navigating the Desert of Cancer: A New Path Forward

The study found that tivozanib was generally well tolerated, with manageable side effects. Furthermore, the researchers observed encouraging clinical activity in patients with renal cell cancer, colorectal cancer, and other tumors. These findings suggest that tivozanib could offer a new and potentially effective treatment option for patients with these cancers.

Hope in the Face of Adversity: The Power of Precision Medicine

Tivozanib's ability to target specific receptors involved in tumor growth represents a promising advancement in precision medicine. By selectively targeting these receptors, tivozanib can potentially disrupt the growth and spread of cancer cells while minimizing harm to healthy cells. This personalized approach to cancer treatment offers hope for patients who have exhausted other options.

Dr. Camel's Conclusion

This research offers a glimmer of hope in the desert of advanced cancer. The findings suggest that tivozanib could be a valuable new weapon in the fight against these challenging diseases. This study underscores the importance of continued research and development in the field of oncology, as new and innovative treatments hold the key to improving the lives of patients with cancer.

Date :
  1. Date Completed 2012-03-25
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

21976547

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-11-0411

Related Literature

Article Analysis
・Side Effects of tivozanib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.